Eric Benevich - Feb 7, 2022 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Stock symbol
NBIX
Transactions as of
Feb 7, 2022
Transactions value $
-$410,821
Form type
4
Date filed
2/9/2022, 05:53 PM
Previous filing
Feb 2, 2022
Next filing
Oct 19, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBIX Common Stock Sale -$65.3K -809 -4.68% $80.68 16.5K Feb 7, 2022 Direct F1, F2
transaction NBIX Common Stock Sale -$164K -2.03K -9.98% $80.83 18.3K Feb 7, 2022 Direct F3, F4
transaction NBIX Common Stock Sale -$103K -1.28K -6.17% $80.78 19.5K Feb 7, 2022 Direct F5, F6
transaction NBIX Common Stock Sale -$78.1K -980 -4.6% $79.67 20.3K Feb 8, 2022 Direct F7, F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale of 809 shares of common stock issued upon vesting of 1,538 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (729) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
F2 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.79 to $81.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 Sale of 2,030 shares of common stock issued upon vesting of 3,856 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (1,826) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
F4 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.72 to $81.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5 Sale of 1,280 shares of common stock issued upon vesting of 2,430 restricted stock units on February 7, 2022 to cover payroll and withholding taxes, with the balance of the shares (1,150) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
F6 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.77 to $81.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F7 Sale of 980 shares of common stock issued upon vesting of 1,859 restricted stock units on February 8, 2022 to cover payroll and withholding taxes, with the balance of the shares (879) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
F8 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $79.08 to $80.21. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F9 Includes an aggregate of 146 shares purchased on August 31, 2021 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.